Skip to main content
. 2017 Oct 27;7:14275. doi: 10.1038/s41598-017-14290-3

Figure 3.

Figure 3

Treatment with ACVR2B/Fc improves muscle function in R6/2 mice. (A–D) Contractile dysfunction of the R6/2 EDL muscles was assessed by measuring twitch tension: the time to peak and half relaxation time and this was corrected by ACVR2B/Fc treatment in both EDL (A,C) and TA (B,D) muscles. (E,F) The maximum tetanic force in mice treated with ACVR2B/Fc and vehicle. The maximum EDL (E) and TA (F) forces were decreased in R6/2 mice and completely rescued in mice treated with ACVR2B/Fc. (G) Examples of motor unit traces and the quantification of functional motor units. The number of functional motor units was reduced in R6/2 EDL muscles and this was restored in treated mice. Statistical analysis was two-way ANOVA with post-hoc Bonferroni correction (see Table S8 for main effects and Table S9 for multiple comparisons). Statistically significant differences between vehicle treated WT and vehicle treated R6/2: # p < 0.05, ### p < 0.001; statistically significant differences between ACVR2B/Fc treated R6/2 and vehicle treated R6/2: *p < 0.05; **p < 0.01; ***p < 0.001. n = 11 WT vehicle (EDL), n = 12 WT vehicle (TA), n = 8 WT ACVR2B/Fc (EDL and TA), n = 14 R6/2 vehicle (EDL and TA), n = 12 R6/2 ACVR2B/Fc (EDL and TA). All data presented as means ± SEM. The baseline WT and R6/2 vehicle treated phenotype data were previously published10.